Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Boston Scientific Continues M&A Spree

Boston Scientific Corp. forked over up to $160 million to acquire California stent maker Veniti Inc. The deal marks the third acquisition for Boston Scientific in two months.

Read More »

Almirall inks $650 million U.S. deal with Allergan

The Spanish pharmaceutical company Almirall agreed to buy five dermatology brands from U.S. company Allergan for up to $650 million in cash.

Read More »

Bayer sells Rx dermatology brands to Leo Pharma

Bayer agreed to sell the German drugmaker’s established prescription dermatology brands to Denmark’s Leo Pharma.

Read More »

Justice Department Gives Go-Ahead To CVS, Aetna Deal

The U.S. Justice Department will not challenge the $69 million merger of CVS Health and health insurer Aetna.

Read More »

Otsuka Pharmaceutical Buying Visterra for $430 Million

Tokyo’s Otsuka Pharmaceutical is acquiring Waltham, Mass.-based Visterra for $430 million in cash. The deal is expected to close during third-quarter 2018.

Read More »

CURE Pharmaceutical to Acquire Cannabinoid-Based Drug Pipeline from Therapix

CURE Pharmaceutical signed a term sheet to acquire the non-pain assets of Therapix Biosciences.

Read More »

Catalent Signs Agreement to Acquire Juniper Pharmaceuticals

Catalent Inc. announced that the drug delivery company agreed to acquire Juniper Pharmaceuticals Inc., including its Nottingham, U.K.-based Juniper Pharma Services division.

Read More »

Interpublic Group to purchase Acxiom Marketing Solutions for $2.3 Billion

Data foundation Acxiom announced a definitive agreement to sell its Acxiom Marketing Solutions business to Interpublic Group for $2.3 billion in cash.

Read More »

Adamis Pharma Sells Epinephrine Injector Rights to Novartis

Adamis Pharmaceuticals is selling U.S. commercial rights to Symjepi, a competitor to Mylan’s EpiPen, to Novartis.

Read More »

Akebia Therapeutics, Keryx Biopharmaceuticals Merge

Akebia Therapeutics announced a merger agreement with Keryx Biopharmaceuticals to create a company expected to be a leader in the development of renal disease therapies.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom